NCT05007106 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05007106
Title	MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	cervical adenocarcinoma cholangiocarcinoma cervical squamous cell carcinoma bile duct adenocarcinoma intrahepatic cholangiocarcinoma endometrial cancer esophagus squamous cell carcinoma cervical adenosquamous carcinoma triple-receptor negative breast cancer esophagus adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma hepatocellular carcinoma
Therapies	MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NLD \| ITA \| ISR \| FRA \| ESP \| DEU \| CAN

No variant requirements are available.